Pfizer Deal Dead as Treasury Cracks Down on Corporate Tax Dodgers
"Issuing what some called a death blow to the proposed $150 billion merger between pharmaceutical giants Pfizer and Allergan, the U.S. Treasury Department late Monday proposed new tax regulations aimed at cracking down on so-called corporate inversions."
